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Abstract
Background: Kabuki syndrome (Niikawa-Kuroki syndrome) is a rare, multiple congenital anomalies/mental
retardation syndrome characterized by a peculiar face, short stature, skeletal, visceral and dermatoglyphic
abnormalities, cardiac anomalies, and immunological defects. Recently mutations in the histone methyl transferase
MLL2 gene have been identified as its underlying cause.
Methods: Genomic DNAs were extracted from 62 index patients clinically diagnosed as affected by Kabuki
syndrome. Sanger sequencing was performed to analyze the whole coding region of the MLL2 gene including
intron-exon junctions. The putative causal and possible functional effect of each nucleotide variant identified was
estimated by in silico prediction tools.
Results: We identified 45 patients with MLL2 nucleotide variants. 38 out of the 42 variants were never described
before. Consistently with previous reports, the majority are nonsense or frameshift mutations predicted to generate
a truncated polypeptide. We also identified 3 indel, 7 missense and 3 splice site.
Conclusions: This study emphasizes the relevance of mutational screening of the MLL2 gene among patients
diagnosed with Kabuki syndrome. The identification of a large spectrum of MLL2 mutations possibly offers the
opportunity to improve the actual knowledge on the clinical basis of this multiple congenital anomalies/mental
retardation syndrome, design functional studies to understand the molecular mechanisms underlying this disease,
establish genotype-phenotype correlations and improve clinical management.
Background
Kabuki syndrome (KS, MIM #147920), also known as
Niikawa-Kuroki syndrome, is a rare, multiple congenital
anomalies/mental retardation syndrome characterized by
a peculiar face, which is defined by long palpebral fis-
sures with eversion of the lateral third of the lower eye-
lids, short columella with a broad and depressed nasal
tip, prominent ears, and a cleft or high-arched palate.
Additional features include short stature, skeletal,
visceral and dermatoglyphic abnormalities, cardiac
anomalies, and immunological defects [1,2]. Kabuki syn-
drome has an incidence of 1 in 32,000, likely largely
underestimated [3]. The vast majority of reported cases
are sporadic. After initial and controversial data that
associated this condition to chromosomal rearrangement
[4,5], mutations in the MLL2 gene identified the under-
lying cause of Kabuki syndrome in approximately 72%
of affected individuals [6,7]. The encoded MLL2 protein
is a member of the Mixed Lineage Leukemia (MLL)
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family of histone methyl transferases (HMT). The MLL
proteins (MLLs) are part of the SET (Su(var)3-9, Enhan-
cer-of-zeste, Trithorax) family of proteins [8]. The
highly conserved SET domain of MLLs confers histone
methyltransferase activity, which is the core function of
HMTs. MLLs are important in the epigenetic control of
active chromatin states [9]. They act as transcriptional
co-activators and are involved in embryogenesis and
development through, for example, regulation of the
expression of the HOX genes and their interaction with
nuclear receptors [10,11].
The MLL2 gene encodes a multi-domain-containing
protein of 5,537 amino acid residues that can methylate
the Lys-4 position of histone H3 (H3K4), an epigenetic
mark correlated with transcriptional active chromatin
[12,13]. MLL2 is involved in estrogen receptor a (ERa)-
mediated signal transduction, acting as a coactivator of
a complex that includes ASH2, RBQ3, and WDR5 [14].
In the present study, by direct sequencing of DNA
samples from 62 Kabuki patients we identified 42 MLL2
variants, 38 of which are novel.
Methods
Subjects and Clinical Data
Our cohort comprised 62 index patients clinically diag-
nosed as affected by Kabuki syndrome (Figure 1 and
Table 1). Patients were enrolled after obtaining appro-
priate informed consent by the physicians in charge and
approval by the respective local ethics committees.
Patients were included in this study whether at least
four of the following inclusion criteria were present: 1)
long palpebral fissures with eversion of the lateral por-
tion of lower eyelid; 2) broad, arched eyebrows with
sparseness; 3) short nasal columella with depressed
nasal tip; 4) large, prominent or cupped ears; 5) devel-
opmental delay-mental retardation [15].
Samples preparation
Genomic DNAs were extracted from fresh and/or frozen
peripheral blood leukocytes of the probands and their
available family members using an automated DNA
extractor and commercial DNA extraction Kits (EZ1,
Qiagen, Hilden, Germany).
PCR-based sequencing of MLL2
Primers were designed using the Primer 3 Output pro-
gram (http://frodo.wi.mit.edu/primer3/) to amplify the
54 coding exons of MLL2 (RefSeq NM_003482.3) gene
including the intronic flanking sequences. Amplicons
and primers were checked both by BLAST and BLAT
against the human genome to ensure specificity. A com-
plete list of primers is reported in Additional file 1,
Table S1. The amplified products were subsequently
purified and sequenced with a ready reaction kit (BigDye
Terminator v1.1 Cycle, Applied Biosystems). The frag-
ments obtained were purified using DyeEx plates (Qia-
gen) and resolved on an automated sequencer (3130xl
Genetyc analyzer DNA Analyzer, ABI Prism). Sequences
were analyzed using the Sequencer software (Gene
Codes, Ann Arbor, Michigan). Whenever possible the
mutations identified were confirmed on a second inde-
pendent blood sample. The issue of whether the novel
MLL2 missense alterations were causative mutations or
neutral polymorphisms was addressed by searching
dbSNP (http://www.ncbi.nlm.nih.gov/SNP) for their pre-
sence; the screening of 100 alleles from healthy unre-
lated control subjects and from the 1000 Genomes
database [16] were used to assess their presence/absence
in the general population. All existing and new muta-
tions were described following the recommendations of
the Human Genome Variation Society (http://www.hgvs.
org/mutnomen).
In silico analysis
The putative causal and functional effect of each iden-
tified nucleotide variant was estimated by using the
following in silico prediction tools: Polyphen http://
genetics.bwh.harvard.edu/pph, Align GVGD http://
agvgd.iarc.fr/agvgd_input.php, and MutPred http://
mutdb.org/profile. Splice sites variants were evaluated
for putative alteration of regulatory process at the
transcriptional or splicing level with NetGene2 http://
www.cbs.dtu.dk/services/NetGene2 and NNSPLICE
http://www.fruitfly.org/seq_tools/splice.html. RESCUE-
ESE http://genes.mit.edu/burgelab/rescue-ese/ and Fas-
ESS http://genes.mit.edu/fas-ess/ online tools were
used to predict exon-splicing enhancer and silencer,
respectively. RepeatMasker http://www.repeatmasker.
org/ was used to screen DNA sequences for the
presence of direct repeats. The Coils program http://
www.ch.embnet.org/software/COILS_form.html was
employed to calculate the probability that the variant
induces a conformational change in the coiled-coil
domains. Finally multiple species alignment of MLL2
protein was made with the ClustalW software http://
www.ebi.ac.uk/Tools/clustalw2/index.html using the
following orthologs sequences obtained through the
Ensembl genome browser http://www.ensembl.org:
P. troglodytes (ENSPTRP00000041051), M. musculus
(ENSMUSP00000023741), C. familiaris (gENSCAFP
00000012833), B. taurus (ENSBTAP00000019193),
X. troplicalis (ENSXETP00000024427), and D. rerio
(ENSDARP00000053862).
Results and Discussion
Exome sequencing recently revealed that mutations in
the histone methyltransferase MLL2 gene are a major
cause of Kabuki syndrome [6]. In a collaborative effort
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that involved Italian Institutes, except one, we enrolled
62 individuals with a clinical diagnosis of sporadic
Kabuki syndrome (Table 1). We detected nucleotide var-
iants in 73% of the patients (45/62) by direct sequencing
of all 54 exons of the MLL2 gene; the vast majority of
which are novel (90%, 38/42 different variants) (Figure
2, Additional file 1, Table S2, Additional file 2,
Figure S1 and below) [6,7].
Nonsense and frameshift mutations
In agreement with previous reports we identified a
majority of truncating mutations (70%, 29/42), three of
Figure 1 Facial features of Kabuki syndrome patients. Representative images of Kabuki patients with MLL2 mutations.
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which were reported previously (Figure 2, Additional
file 1, Table S2) [6,7]. Most of the variants are predicted,
if translated, to encode shorter MLL2 proteins either by
loss of the entire C-terminal region or parts of it
(Figure 2). This region harbors highly conserved domains
that are found in a variety of chromatin-associated pro-
teins [17-19]: (i) the helical LXXLL regions involved in
the recruitment of the MLL2 complex to the promoters
of ERa target genes (Figure 2); (ii) FYRN and FYRC
sequence motifs, two poorly characterized phenylalanine/
tyrosine-rich regions of around 50 and 100 amino acids
[20], respectively; and (iii) a catalytic SET motif that con-
fers histone methyltransferases activity.
Although it has not been yet experimentally verified
for the MLL2 gene, the prevalence of premature termi-
nation mutations may result in the partial transcripts
degradation through nonsense-mediated mRNA decay
(NMD). NMD is an evolutionarily conserved process
that typically degrades transcripts containing premature
termination codons (PTCs) to prevent translation of
unnecessary or aberrant and possible transcripts [21].
The NMD process takes place when PTCs are located
more than 50-55 nucleotides upstream of an exon-exon
junction [22]. As 86% (25/29) of such detected MLL2
mutations follow this rule it is likely that the consequent
MLL2 haploinsufficiency could be the driving force for
the onset of the Kabuki syndrome.
Indel variants
Our screen revealed three not yet described indel variants
located in the C-terminal region of the protein (see sam-
ples KB71, KB77, and KB53 in Additional file 1, Table
S2). They might have resulted from slipped mispairing
between direct repeats or through the insertion or dele-
tion of a single base within a mononucleotide tract
(Additional file 1, Table S3), as already reported [23].
COILS algorithm predicted the amplification of one of
the five coiled-coil putative domains for the
c.11819_11836dupTTCAACAACAGCAGCAGC (p.
Lys3940_Gln3945dup) (Figure 2 and data not shown), a
domain involved in protein-protein interaction. This
variant was inherited from the apparently asymptomatic
mother. It is thus impossible to conclusively determine
the pathogenic nature of the resulting protein.
Splice site variants
We detected 3 variants located at the splice site junc-
tions, two of which are novel [7] (Additional file 1,
Table S2); the in silico modeling predicted complete or
partial abrogation of the junction formation with a
pathogenic impact. The c.400+1G>A, occurring within
the invariant GT donor splice site in intron 3-4, results
in the disruption of the canonical splice site and it is
expected to produce an aberrant protein of only 135
residues. The c.401-3A>G, occurring 3 bp away from
the next intron-exon junction, is predicted to create a
new acceptor splice site at position -3 within intron 3-4
that could lead to a frameshift encoding a mutant pro-
tein with a premature stop at 84 codons downstream.
Finally, c.13999+5G>A decreases the donor site score
prediction, possibly resulting in a less efficient intron
splicing. Unfortunately, RNA from these patients was
unavailable preventing further investigation of the effect
of these variants.
Table 1 Clinical features of our cohort of Kabuki
syndrome patients
Gender 36/62 (58.1%) Male
26/62 (41.9) Female
General features
Short stature 38/62 (61.2)
Microcephaly 18/62 (29)
Neonatal problems 42/62 (67.7)
Facial
Long palpebral fissures 59/62 (95.2)
Everted lower eyelids 53/62 (85.5)
Large dysplastic ears 56/62 (90.3)
Arched eyebrows, sparse lateral one third 51/62 (82.2)
Flat nasal tip 43/62 (69.3)
Abnormal dentition 33/62 (53.2)
High/cleft palate 37/62 (59.7)
Strabismus 26/62 (41.9)
Blue sclerae 11/62 (17.7)
Micrognathia 20/62 (32.2)
Ptosis 32/62 (51.6)
Broad nasal root 39/62 (62.9)
Oligodontie 23/62 (37.1)
Thin upper and full lower lip 44/62 (71)
Limb/skeletal
Persistent fetal pads 47/62 (75.8)
Brachy/clinodactyly 39/62 (62.9)
Lax joints 30/62 (48.4)
Hip dislocation 8/62 (12.9)
Visceral anomalies
Cardiac anomalies 37/62 (59.7)
Urogenital anomalies 24/62 (38.7)
Neurologic
MR 52/62 (83.9)
Hypotonia 37/62 (59.7)
Seizures 13/62 (21.4)
Other clinical features (most recurrent)
frequent infections 26/62 (41.9)
leftearly breast development 10/62 (16.1)
lefthypoacusia 7/62 (11.3)
skeletal anomalies 6/62 (9.7)
leftthyroid anomalies 4/62 (6.9)
leftagenesis/dysgenesis corpus callosum 3/62 (5.2)
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Missense variants
Missense de novo variants have already been found in
Kabuki patients. Ng and colleagues reported 8 patho-
genic missense variants, two of which were recurrent in
affected patients. As these were all mapping within the
last exon of MLL2 that encodes the different conserved
C-terminal domains of the protein (see above), the
authors suggested that such mutations are tolerated,
while mutations elsewhere are lethal. By in silico analy-
sis, Paulussen et al. proposed the pathogenicity of two
missense variants located within that C-terminal region
[6,7]. We detected seven patients with a single or two
missense variants (KB28 and KB38 patients; Additional
file 1, Table S2). PCR amplification, cloning and sequen-
cing showed that both sets of the two sequence changes
in KB28 and KB38 patients are located on one allele.
From a phenotypic point of view, the two patients with
pairs of missense variants do not appear to be more
severely affected than affected individuals with single
variants. Sequencing of the corresponding exons in the
KB38 parents demonstrated that both variants arose de
novo, while the KB28 patient inherited the variant from
the apparently asymptomatic mother. We had also
accessed to DNA of parents of carriers of missense var-
iants (Additional file 1, Table S2). Yet, in both cases the
MLL2 variant was inherited from the apparently asymp-
tomatic father.
The missense variants are distributed across the
entire length of the MLL2 gene (Figure 2). They were
not found in 50 healthy unrelated control samples and
were absent from the 1000 Genomes database [16].
The putative functional relevance and pathogenicity of
these MLL2 missense variants were predicted by in
silico software. The PolyPhen program, which predicts
possible impact of an amino acid substitution on the
structure and function of a human protein, identified
only the p.Pro2841Thr variant as possibly damaging.
Accordingly to the criteria of Align-GVGD all mis-
sense variants were predicted to be deleterious (Table
2). Finally, we used the computational model MutPred,
designed to classify an amino acid substitution as dis-
ease-associated or neutral in human. MutPred pre-
dicted that four of the identified missense variants
have a high probability (≥0,5) of being deleterious and
generated in silico hypothesis for the possible patholo-
gical mechanism for three of them (Table 2). The ana-
lysis of the mutated residues in 7 MLL2 proteins
orthologs showed that.all the missense variants
occurred at amino acid residues evolutionarily con-
served (Figure 2).
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Figure 2 Mutation spectrum of MLL2 in our cohort of Kabuki syndrome patients. Upper panel: genomic structure of the MLL2 gene
including 54 coding exons (black rectangles), the 3’untranslated region (red rectangle) and introns (black horizontal line). Mutations are
represented in black (nonsense = 16), red (indel = 3), blue (splice sites = 3), and green (frameshift = 13). Middle figure: MLL2 protein domain
structures, PHD, plant homeodomain finger; HMG-box, high mobility group; CC, Coiled Coil; LXXLL domain, FYRN, FY-rich domain, N-terminal
region; FYRC, FY-rich domain, C-terminal region; SET, (Su(var)3-9, Enhancer-of-zeste, Trithorax) domain; PostSET: PostSET domain. Lower panel:
evolutionary comparison of the protein sequences flanking the 7 missense mutations identified in the human MLL2 protein with their
orthologous counterparts in seven species. The position of the amino acid change is indicated with a star.
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Table 2 In silico prediction of pathogenic effect of MLL2 missense and splice site variants
Prediction of damaging effect at the protein level
ID Exon Mutation AA change MutPred Rescue-ESE Fas-ESS
Polyphen Align GVGD Probability of
deleterious mutation
Confident in silico
hypothesis
KB32 11 c.3773G>A p.Arg1258Gln benign deleterious 0.16 loss of loop (p = 0.0288,
loss of catalytic
residue at R1258 (p =
0.0301); gain of helix
(p = 0.0349)
no change no change
KB28 15 c.[4249A>G;4252C>A] p.[Met1471Val;
Leu1418Met]
benign; benign deleterious; deleterious 0.46; 0.47 none; none no change gain of one
ESS
KB34 16 c.4565A>G p.Gln1522Arg benign deleterious 0.50 none loss of one
ESE
no change
KB27 34 c.8521C>A p.Pro2841Thr possibly damaging deleterious 0,24 gain of phoshorylation P2841
(p = 0.028)
gain of two
ESEs
loss of one
ESS
KB38 48 c.[15084C>G;15100T>G] p.[Asp 5028Glu;
Phe5034Val]
benign; benign deleterious; deleterious 0.42; 0.56 none; none gain of
three ESEs
loss of
three ESSs
KB76 48 c.1517A>C p.His5059pro benign deleterious 0,71 none no change no change
KB17 50 c.16019G>A p.Arg5340Gln benign deleterious 0,53 gain of ubiquitination at
K5344 (p = 0.0396)
gain of two
ESEs
no change
ID Intron Mutation Splice site modification prediction Predicted Protein Conclusion
NetGene NNSplice
KB31 Intron 3-4 c.400+1G>A Loss of DS Loss of DS 135 AA with novel 2 AA deleterious
KB20 Intron 3-4 c.401-3A>G New AS at-3 New AS at-3 217 AA with novel 84 AA deleterious
KB29 Intron 42-43 c. 13999+5 G>A Lower confidence of DS
prediction
Lower confidence of DS
prediction
unpredictable
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Finally, we employed RESCUE-ESE and Fas-ESS
tools on missense variants and frameshift mutations to
predict associated splicing phenotypes by identifying
sequence changes that disrupt or alter predicted Exo-
nic Splicing Enhancers (ESE) and Exonic Splicing
Silencers (ESS). ESE and ESS are short oligonucleo-
tides that can enhance or inhibit pre-mRNA splicing
when present in exons, playing important roles in con-
stitutive and alternative splicing. A variation that dis-
rupts an ESE, for instance, could cause exon skipping
which would result in the exclusion of an entire exon
from the mRNA transcript. Conversely, a substitution
in the ESS sequence promotes the use of adjacent
splice sites, often contributing to alternative splicing.
As reported in Table 2 and Additional file 1, Table S3,
we found that some of the MLL2 mutations lead to
creation of new ESEs and/or to disruption of predicted
wild type ESEs/ESSs. As secondary structures or adja-
cent negative elements also participate to the modula-
tion of the splicing event mediated by ESE and ESS,
we retain that association to functional studies will
enable to better understand the role of the reported
cases of ESEs/ESSs disruption or alteration in the
complex phenotypic spectrum observed in the Kabuki
patients.
Conclusions
Our study increases the number of identified MLL2
mutations and variants, and emphasizes some character-
istics of the spectrum of MLL2 mutations associated
with this pathology, further providing insight into its
etiology. The in silico analysis predicts that the identi-
fied MLL2 missense, splice-site and indel variants might
be pathogenic. Other studies reported the presence of
such MLL2 variants predicted to be associated with the
disease. However, their biological significance and
pathogenicity were not unambiguously demonstrated;
therefore further and more functionally oriented studies
are needed to understand the nature of these variants
and their possible role in the disease. Solving these
issues is relevant to avoid any incorrect interpretation
and diagnosis of other Kabuki cases carrying such MLL2
variants.
We were unable to found any detectable point muta-
tion and/or small del/dup in the coding region of MLL2
gene in 27% (17/62) of the Kabuki syndrome patients.
Mutations in MLL2 regulatory regions, exon microdupli-
cations and/or microdeletions, as well as genetic hetero-
geneity of the syndrome may account for these negative
results. Alternatively, some of these patients might have
been misdiagnosed as a result of the complex clinical
spectrum covered by this pathology, thus possibly high-
lighting the need to more accurately select Kabuki cases
before conducting the analysis.
In summary, this study underlines the relevance of
mutational screening of the MLL2 gene among patients
with Kabuki syndrome. The identification of a large
spectrum of MLL2 mutations will offer the opportunity
to improve the actual knowledge on the clinical basis of
this multiple congenital mental retardation syndrome, to
design functional studies to understand the molecular
mechanisms underlying the disease, to establish geno-
type-phenotype correlations, to improve the clinical
management, and to identify potential targets for
therapy.
Additional material
Additional file 1: Table S1. Oligos used in this study. Table S2. MLL2
mutations identified in our cohort of KS patients and as reported in the
literature. Table S3. Repeats (underlined and highlighted in red) that
might mediate micro-deletions, micro-insertion/deletions (indel), and
micro-duplications in the MLL2 gene.
Additional file 2: Figure S2. Frequency of different MLL2 mutation
types in Kabuki syndrome patients identified to date. Our study (A), Ng et
al. and Paulussen et al. studies (B), all three studies, A+B, (C).
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